CD5L and neoplasm: While the potential tumor burden markers (YWHAE, PFN1, LCP1, IGHM, CD5L) are relatively abundant in CSF and have been previously implicated in various malignancies beyond CNSL, our study uniquely demonstrates their value in monitoring CNSL disease progression and treatment response.